Trial Outcomes & Findings for A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures (NCT NCT02519439)

NCT ID: NCT02519439

Last Updated: 2023-06-28

Results Overview

Baseline 28-day seizure frequency was calculated as the number of seizures in the Baseline period of Study 1042-0603 (less than or equal to 56 days) divided by the number of days with available seizure data in the Baseline period and multiplied by 28. Post-baseline 28-day seizure frequency was calculated as the number of seizures in the entire treatment period divided by the number of days with available seizure data in the treatment period and multiplied by 28. Baseline was defined as the last non-missing value obtained before the first treatment in the preceding Study 1042-0603. The calculation for percent change from Baseline in 28-day seizure frequency was done as follows for each participant: post-Baseline 28-day seizure frequency minus Baseline 28-day seizure frequency whole divided by Baseline 28-day seizure frequency multiplied by 100 percent.

Recruitment status

TERMINATED

Study phase

PHASE3

Target enrollment

26 participants

Primary outcome timeframe

Baseline and at Day 28

Results posted on

2023-06-28

Participant Flow

This was an open-label extension of Study 1042-0603, providing a two-year adjunctive ganaxolone treatment to adult participants with epilepsy consisting of partial-onset seizures (POS).

A total of 26 participants moved in from 1042-0603 (NCT01963208) study. As Ganaxolone missed its primary endpoint in the double-blind portion of the 1042-0603 study, the study was terminated.

Participant milestones

Participant milestones
Measure
Ganaxolone
Participants entered the study at their current dose of ganaxolone (450 milligrams \[mg\] to 900 mg twice daily; up to a maximum dose of 1800 mg per day) from Study 1042-0603 (NCT01963208). The dose of ganaxolone has been adjusted for tolerability and response.
Overall Study
STARTED
26
Overall Study
COMPLETED
5
Overall Study
NOT COMPLETED
21

Reasons for withdrawal

Reasons for withdrawal
Measure
Ganaxolone
Participants entered the study at their current dose of ganaxolone (450 milligrams \[mg\] to 900 mg twice daily; up to a maximum dose of 1800 mg per day) from Study 1042-0603 (NCT01963208). The dose of ganaxolone has been adjusted for tolerability and response.
Overall Study
Study Termination
19
Overall Study
Withdrawal by Subject
1
Overall Study
Adverse Event
1

Baseline Characteristics

A Two-year Open-label Extension Study of Ganaxolone in Patients With Drug-resistant Partial-onset Seizures

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Ganaxolone
n=26 Participants
Participants entered the study at their current dose of ganaxolone (450 milligrams \[mg\] to 900 mg twice daily; up to a maximum dose of 1800 mg per day) from Study 1042-0603 (NCT01963208). The dose of ganaxolone has been adjusted for tolerability and response.
Age, Continuous
44.3 Years
STANDARD_DEVIATION 15.03 • n=5 Participants
Sex: Female, Male
Female
11 Participants
n=5 Participants
Sex: Female, Male
Male
15 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
23 Participants
n=5 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=5 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=5 Participants
Race (NIH/OMB)
Asian
0 Participants
n=5 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=5 Participants
Race (NIH/OMB)
White
24 Participants
n=5 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=5 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Baseline and at Day 28

Population: Full Analysis Population included participants who returned at least 25 days of seizure calendar data.

Baseline 28-day seizure frequency was calculated as the number of seizures in the Baseline period of Study 1042-0603 (less than or equal to 56 days) divided by the number of days with available seizure data in the Baseline period and multiplied by 28. Post-baseline 28-day seizure frequency was calculated as the number of seizures in the entire treatment period divided by the number of days with available seizure data in the treatment period and multiplied by 28. Baseline was defined as the last non-missing value obtained before the first treatment in the preceding Study 1042-0603. The calculation for percent change from Baseline in 28-day seizure frequency was done as follows for each participant: post-Baseline 28-day seizure frequency minus Baseline 28-day seizure frequency whole divided by Baseline 28-day seizure frequency multiplied by 100 percent.

Outcome measures

Outcome measures
Measure
Ganaxolone
n=26 Participants
Participants entered the study at their current dose of ganaxolone (450 milligrams \[mg\] to 900 mg twice daily; up to a maximum dose of 1800 mg per day) from Study 1042-0603 (NCT01963208). The dose of ganaxolone has been adjusted for tolerability and response.
Percent Change From Baseline in 28-day Seizure Frequency
-41.86 Percent change
Standard Deviation 44.913

SECONDARY outcome

Timeframe: Baseline and at Day 28

Population: Full Analysis Population.

A 50% responder is an individual whose reduction of percent change from Baseline to the end of the open label extension period in 28-day partial-onset seizure (POS) seizure frequency is greater than or equal to 50%.

Outcome measures

Outcome measures
Measure
Ganaxolone
n=26 Participants
Participants entered the study at their current dose of ganaxolone (450 milligrams \[mg\] to 900 mg twice daily; up to a maximum dose of 1800 mg per day) from Study 1042-0603 (NCT01963208). The dose of ganaxolone has been adjusted for tolerability and response.
Number of Participants Who Showed Greater Than or Equal to 50% Reduction in 28-day Seizure Frequent From Baseline
14 Participants

SECONDARY outcome

Timeframe: At Week 104

Population: Safety Population included all participants who signed informed consent and took one dose of study medication in this study. Only those participants with data available at indicated timepoints has been presented.

The CGI-I scale is a clinician-rated 7-point scale used to assess how much the participant's illness had improved or worsened relative to a Baseline state at the beginning of the intervention. It was rated as: 1. "very much improved" 2. "much improved" 3. "minimally improved" 4. "no change" 5. "minimally worse" 6. "much worse" 7. "very much worse". Higher scores indicated worse condition. Participants who showed CGI improvement at Week 104 (End of treatment) has been presented.

Outcome measures

Outcome measures
Measure
Ganaxolone
n=23 Participants
Participants entered the study at their current dose of ganaxolone (450 milligrams \[mg\] to 900 mg twice daily; up to a maximum dose of 1800 mg per day) from Study 1042-0603 (NCT01963208). The dose of ganaxolone has been adjusted for tolerability and response.
Number of Participants With Clinical Global Impression of Improvement (CGI-I) Scores
Very much improved
1 Participants
Number of Participants With Clinical Global Impression of Improvement (CGI-I) Scores
Much improved
9 Participants
Number of Participants With Clinical Global Impression of Improvement (CGI-I) Scores
Minimally improved
11 Participants
Number of Participants With Clinical Global Impression of Improvement (CGI-I) Scores
No change
2 Participants
Number of Participants With Clinical Global Impression of Improvement (CGI-I) Scores
Minimally worse
0 Participants
Number of Participants With Clinical Global Impression of Improvement (CGI-I) Scores
Much worse
0 Participants
Number of Participants With Clinical Global Impression of Improvement (CGI-I) Scores
Very much worse
0 Participants

SECONDARY outcome

Timeframe: At Week 104

Population: Safety Population. Only those participants with data available at indicated time points has been presented.

The participant is asked to rate the total improvement of their partial-onset seizures whether or not in the participant's judgment it is due entirely to drug treatment based on a 7-point scale using the markers "very much improved, much improved, slightly improved, no change, slightly worse, much worse, or very much worse" (1 = very much improved; 7 = very much worse). Higher scores indicated worse condition. Participants who showed PGI improvement at Week 104 (End of treatment) has been presented.

Outcome measures

Outcome measures
Measure
Ganaxolone
n=23 Participants
Participants entered the study at their current dose of ganaxolone (450 milligrams \[mg\] to 900 mg twice daily; up to a maximum dose of 1800 mg per day) from Study 1042-0603 (NCT01963208). The dose of ganaxolone has been adjusted for tolerability and response.
Number of Participants With Patient/Caregiver Global Impression of Improvement (PGI-I) Scores
Very much improved
4 Participants
Number of Participants With Patient/Caregiver Global Impression of Improvement (PGI-I) Scores
Much improved
8 Participants
Number of Participants With Patient/Caregiver Global Impression of Improvement (PGI-I) Scores
Minimally improved
10 Participants
Number of Participants With Patient/Caregiver Global Impression of Improvement (PGI-I) Scores
No change
1 Participants
Number of Participants With Patient/Caregiver Global Impression of Improvement (PGI-I) Scores
Minimally worse
0 Participants
Number of Participants With Patient/Caregiver Global Impression of Improvement (PGI-I) Scores
Much worse
0 Participants
Number of Participants With Patient/Caregiver Global Impression of Improvement (PGI-I) Scores
Very much worse
0 Participants

Adverse Events

Ganaxolone

Serious events: 1 serious events
Other events: 10 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Ganaxolone
n=26 participants at risk
Participants entered the study at their current dose of ganaxolone (450 milligrams \[mg\] to 900 mg twice daily; up to a maximum dose of 1800 mg per day) from Study 1042-0603 (NCT01963208). The dose of ganaxolone has been adjusted for tolerability and response.
Respiratory, thoracic and mediastinal disorders
Pulmonary embolism/
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.

Other adverse events

Other adverse events
Measure
Ganaxolone
n=26 participants at risk
Participants entered the study at their current dose of ganaxolone (450 milligrams \[mg\] to 900 mg twice daily; up to a maximum dose of 1800 mg per day) from Study 1042-0603 (NCT01963208). The dose of ganaxolone has been adjusted for tolerability and response.
Nervous system disorders
Headache
11.5%
3/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Nervous system disorders
Dizziness
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Nervous system disorders
Syncope
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Infections and infestations
Cellulitis
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Infections and infestations
Nasopharyngitis
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Infections and infestations
Tooth infection
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Infections and infestations
Upper respiratory tract infection
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Injury, poisoning and procedural complications
Fall
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Injury, poisoning and procedural complications
Ligament sprain
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Injury, poisoning and procedural complications
Lip injury
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Eye disorders
Lacrimal disorder
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Eye disorders
Vision blurred
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Gastrointestinal disorders
Abdominal pain upper
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Gastrointestinal disorders
Nausea
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
General disorders
Pyrexia
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Hepatobiliary disorders
Cholecystitis chronic
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Investigations
Hepatic enzyme increased
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Metabolism and nutrition disorders
Hypercholesterolaemia
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Musculoskeletal and connective tissue disorders
Back pain
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Musculoskeletal and connective tissue disorders
Neck pain
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Psychiatric disorders
Insomnia
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Renal and urinary disorders
Calculus ureteric
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Respiratory, thoracic and mediastinal disorders
Epistaxis
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Skin and subcutaneous tissue disorders
Seborrhoeic dermatitis
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.
Vascular disorders
Hypertension
3.8%
1/26 • Up to Week 104
Adverse events and Serious adverse events were collected in Safety Population.

Additional Information

Marinus Clinical Trials Submission Manager

Marinus Pharmaceuticals, Inc.

Phone: 484-801-4670

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place